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An active site mutant bovine prothrombin cDNA 
(Serfiz8+Ala) has been  constructed,  subcloned,  and  ex- 
pressed  in  Chinese  hamster  ovary cells. The recombi- 
nant mutant prothrombin, expressed at the level of 
1.5-2.0 wg/ml  of cell  medium, was  fully  carboxylated 
(9.9 f 0.4 mol of y-carboxyglutamic  acid/mol of pro- 
thrombin).  The  mutant  prothrombin could be  activated 
to thrombin by Taipan  snake venom and  activated  to 
meizothrombin by ecarin  in a manner  comparable  to 
native bovine prothrombin  or  recombinant  wild-type 
bovine  prothrombin.  The  mutant  meizothrombin  thus 
formed  was  stable  and  did  not aut lyze. The  initial  rate 
of cleavage of mutant  prothrombin  catalyzed  by  the 
full  prothrombinase  was  only  28% of the  rate of cleav- 
age of native  prothrombin,  while  recombinant  wild- 
type  prothrombin  was cleaved at  the  same  rate as the 
native molecule. The  mutant  thrombin,  obtained  from 
the  mutant  prothrombin in situ by prothrombinase  or 
Taipan  snake venom activation, showed no enzymatic 
activity  toward  either  fibrinogen  or a synthetic  chro- 
mogenic substrate, D-phenylalanyl-L-pipecolyl-bar- 
ginine-p-nitroanilide  dihydrochloride  (52238).  The 
mutant  hrombin  also  bound  dansylarginine-N-(3- 
ethyl-  1,5-~entanediyl)amide, a specific  fluorescent  in- 
hibitor of the thrombin active site, with a weaker 
binding affinity (kd = 5.4 X lo-' M) than  did  native 
thrombin (kd = 1.7 X lo-' M). These results indicate 
that the mutant recombinant prothrombin described 
here is a useful tool for  the  study of meizothrombin or 
thrombin  without  the complications arising  from  the 
proteolytic  activities of these molecules. Study of the 
activation of this  mutant  has  already  revealed a func- 
tional  link  between the site of initial  cleavage  by the 
prothrombinase  and  the  conformation at the nascent 
active  site of prothrombin. 
Prothrombin is the  precursor of thrombin, a serine  protease 
which  plays  a central role in  the process of blood coagulation 
(Mann et al., 1988). The  activation of bovine prothrombin  to 
thrombin requires cleavage of two peptide  bonds, Arg3"3-Ile:'24 
and  Arg274-Thr275. Cleavage at  Arg32"-Ile324 results  in  exposure 
of the active site and formation of meizothrombin, and, if 
al., 1981; Rosing and  Tans, 1988).  Like all  other  serine  pro- 
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Arg274-Thr277" has already been cleaved, thrombin (Mann et 
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teases,  the  thrombin active site  contains  the  catalytic  triad, 
composed of His366, Asp4", and Ser5". 
The activity of thrombin active site toward fibrinogen, 
factor V, factor VIII, factor  XIII,  and  platelets  makes  it very 
difficult to measure the  thrombin  binding  to  those  substrates 
without activation. The cleavage of Arg'"-Ser'57 in bovine 
prothrombin and of both Arg155-Ser156 and  ArP6-Thrza7  in 
human prothrombin by either thrombin or the activation 
intermediate  meizothrombin also creates  an obstacle to  the 
crystallization of prothrombin or to biophysical studies of 
meizothrombin. Meizothrombin undergoes  autolysis  even in 
the  presence of potent  active  site  inhibitors  (Armstrong et al., 
1990; Doyle and  Mann, 1990; Pei  and  Lentz,  1991).  Therefore, 
it is desirable to have an  active  site  mutant of prothrombin. 
A wild-type  human prothrombin cDNA has been  expressed 
in Chinese hamster ovary cells (CHO),' and the expressed 
recombinant  prothrombin  has  been shown to  be  equivalent  to 
plasma-derived  prothrombin  in specific coagulant activity  and 
in y-carboxyglutamic acid content  (Jorgensen et al., 1987).  A 
series of point mutations in the amino-terminal region of 
prothrombin were successively made to identify the amino 
acid  residues in  the  y-carboxylation recognition site  (Huber 
et al., 1990). In the study reported here, a wild-type bovine 
prothrombin  cDNA  and  an active site mutant (Ser5"+Ala) 
bovine prothrombin cDNA have been constructed and ex- 
pressed  in  CHO cells. The  mutant  recombinant  prothrombin 
obtained was fully y-carboxylated,  and was activated at  sim- 
ilar  rates by ecarin  and  Taipan  snake venom and at a slower 
rate by the full prothrombinase  as  compared  to  native  pro- 
thrombin or wild-type recombinant  prothrombin.  The  mutant 
thrombin  had  no  activity  toward fibrinogen or  toward a syn- 
thetic chromogenic substrate (S2238) and displayed a mod- 
erately decreased binding  affinity  toward dansy1arginine-N- 
(3-ethyl-1,5-pentanediyl) amide  (DAPA), a specific thrombin 
active  site  inhibitor. 
EXPERIMENTAL  PROCEDURES 
Materials-Bovine brain  phosphatidylserine (PS) and  l-palmitoyl- 
2-oleoyl-3-sn-phosphatidylcholine (PC) were purchased from Avanti 
Biochemicals (Birmingham, AL).  DAPA was synthesized  and purified 
according to Mann et al. (1981). D-Phenylalanyl-L-pipecolyl-L-argi- 
nine-p-nitroanilide dihydrochloride  (S2238)  was  from Helena  Labo- 
ratories  (Beaumont,  TX).  Ecarin from Echis  carinatus snake venom 
and Taipan snake venom from Oxyurunus scutellatus were from 
Sigma. Morpholine was obtained from Aldrich and formaldehyde 
I The abbreviations used are: CHO,  Chinese  hamster ovary; S2238, 
D-phenylalanyl-L-pipecolyl-L-arginine-p-nitroanilide dihydrochlo- 
ride; DAPA, dansylarginine-N-(3-ethyl-1,5-pentanediyl)amide; PS, 
bovine brain  phosphatidylserine;  PC, 1-palmitoyl-2-oleoyl-3-sn-phos- 
phatidylcholine; ITS,  insulin-transferrin-sodium  selenite media sup- 
plement; SUV, small unilamellar vesicles; SDS-PAGE, sodium do- 
decyl sulfate-polyacrylamide gel electrophoresis; Gla, y-carboxyglu- 
tamic acid. 
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(37% aqueous solution) was from Mallinckrodt (St. Louis, MO). 
["C]Formaldehyde was purchased from Du  Pont-New  England  Nu- 
clear. Insulin-transferrin-sodium selenite media supplement (ITS) 
and NuSerum'" were from Collaborative Research (Bedford, MA). 
Cell growth  medium  Dulbecco's  modified  Eagle's  medium/F-12 and 
calf serum were obtained  from  Linberger  Cancer  Research  Center, 
University of North  Carolina,  Chapel Hill. 
Isolation of bovine prothrombin  and  preparation of small  unila- 
mellar vesicles (SUV) of PS and  PC  (PS/PC, 25/75) were as described 
(Tendian  and  Lentz, 1990). Factor X and  factor V were isolated  from 
human  plasma by procedures routinely used in  our  laboratory  (Cuts- 
forth  et al., 1989). Factor X was activated  with a  purified fraction of 
Russel's viper venom factor X-activating protein which had been 
covalently linked  to agarose  beads (Jesty  and  Nemerson, 1976). Factor 
V was activated by 1.25 ng/ml factor V-activating protein isolated 
from  Russell's  viper  venom  (Kisiel and  Canfield, 1981) in situ. Throm- 
bin was generated  and purified  according to  the procedure of Church 
and  Whinna (1986) and was coupled to  agarose beads (Affi-Gel 10, 
Bio-Rad) following the instructions provided by Bio-Rad. Rabbit 
antisera were raised against purified  bovine thrombin using incom- 
plete  Freund's  adjuvant.  Protein  concentrations were determined by 
absorbance  measurements  using  extinction coefficients a t  280 nm of 
1.44 ml mg" cm" for prothrombin and 1.05 ml mg"  cm" for 
prothrombin  fragment 1 (Mann, 1976). 
Construction of Expression  Plasmids, Wild-type and  Mutant Bovine 
Prothrombin cDNA Clones-The expression vector used for these 
experiments was a derivative of a shuttle vector,  pDx, from  Dr. K. 
Berkner, ZymoGenetics (Seattle, WA). pDx was modified by the 
insertion of an assembled pair of oligonucleotides (aattcactcga- 
gagcggccgc and aattgcggccgctctcgagtg) into the unique EcoRI site. 
This placed  a unique  NotI  site  immediately  downstream of the  unique 
EcoRI  site.  The  resulting  plasmid was called p272 (details  not  shown). 
New subcloning  vectors were also  constructed. p287  was  derived from 
pBS(-)  (Stratagene,  San Diego) by cloning a small oligonucleotide 
fragment (agcttccatggtcgcgactcgagctgca and gctcgactcgcgaccatgga) 
encoding a NcoI restriction  site between the  HindIII  and  PstI sites. 
p431 was constructed by inserting an oligonucleotide fragment 
(agcttgcggccgcctgcaggatatcccatggtggccag amd aattctggccaccatggga- 
tatcctgcaggcggccgca) encoding  NotI,  PstI,  and NcoI sites between the 
HindIII  and  EcoRI  sites of p287. 
Two  plasmids,  pBII-3  and pBII-111, containing  amino-  and  car- 
boxyl-terminal  portions of bovine prothrombin were obtained from 
Ross MacGillivray,  University of British  Columbia (MacGillivray et 
al., 1980). The  prothrombin-coding  sequence  containing  the  initiating 
methionine codon is located within a unique NcoI restriction enzyme 
recognition site  in pBII-111. To  obtain a full-length bovine prothrom- 
bin cDNA, we subcloned the 450-base pair PstI-BamHI fragment 
from pBII-3  and  the 1500-base pair  NcoI-BamHI  fragment  into p287 
(Fig.  1A). The resulting clone was called p429. The  NcoI-PstI frag- 
ment of p429, containing  the  complete  prothrombin  cDNA was sub- 
cloned  into p431 to form p433. Hence, p433 contains a unique  NotI 
site at   the 3' end of the  prothrombin  cDNA (Fig. 1A).  The  prothrom- 
bin expression  vector,  p437  (Fig. lC), was constructed by  subcloning 
the EcoRI-Not1 fragment of p433 into  the  shuttle vector p272. 
The 500-base pair BamHI-Hind111 fragment from  p433 encoding 
the  carboxyl-terminal region of prothrombin was  subcloned into  pUC- 
8, resulting  in a  clone  called p479 (Fig. 1B).  To  mutate  the active site 
serine (Ser"") to  alanine, we replace the  BamHI-Ban11  fragment of 
p479 with a fragment assembled from  four  synthetic oligonucleotides 




gtcggtgatgcg. The BamHI-Hind111 fragment of p481 was subcloned 
into p433, resulting  in p485  (see Fig. 1B).  The region of  Ser5"+Ala 
was sequenced  by the dideoxynucleotide method  (Sanger  et al., 1977) 
to  confirm  the  presence of the SerSz8+Ala mutation  and  the lack of 
other undesirable mutations. The EcoRI-Not1  fragment of p485 was 
subcloned  into p272. The result  is a shuttle expression  vector,  p487 
(Fig. IC)  that  has  the  potential  to  express Ser5"+Ala prothrombin. 
Expression of Mutant  and Wild-type Prothrombin  in CHO Cells- 
Calcium phosphate  cotransformation of CHO was carried  out  using 
a 1 : l O  ratio of p437 or p487 to pRSVneo according to  a standard 
protocol (Graham  and  van  der  Eb, 1973).  Cells were grown in  Dul- 
becco's modified Eagle's medium/F-12  with 10% calf serum  and 500 
pg/ml G418, a neomycin analog  (GIBCO  Bethesda  Research  Labo- 
ratory). Individual  clones of CHO cells resistant  to G418 were tested 
for production of prothrombin.  Nearly  confluent cells were washed 
twice in Dulbecco's modified Eagle's medium/F-lP/ITS  and 10 pg/ 
ml vitamin K. Two ml of media was left on  each  plate for 24 h. The 
media  from the  CHO cells transformed  with wild-type prothrombin 
expression  vector were tested for their  ability  to hydrolyze Spectro- 
zyme TH  as  recommended by the supplier (American Diagnostica, 
NY) upon activation with ecarin. Six colonies produced significant 
levels of prothrombin. One of these has been used for the studies 
presented below. The media  from CHO clones  producing the  mutant 
form of prothrombin were assayed for production of prothrombin 
using Western  blot  analysis  with  the  rabbit  antisera. One  clone that 
produced detectable levels of mutant  prothrombin  has been  used for 
the  studies.  Stocks of cells were maintained  in Dulbecco's modified 
Eagle's medium/F-12  with 5.0% NuSerum, 5.0% calf serum,  and 500 
Kg/ml G418. 
To scale up cell production, one confluent 100-mm plate was 
transferred  to  one roller bottle  (Costar, 900 cm') in a total volume of 
250 ml. In  about 4  days, the cells were confluent. Sterile microcarrier 
beads (0.8 g, Pharmacia  LKB Biotechnology,  Inc.,  Cytodex 2),  diluted 
in 50 ml of growth medium, were added  to  each bottle. After 3  days, 
when the  beads were covered with cells, they were washed  once briefly 
with  serum-free medium and once  again  overnight. All medium was 
removed, and  each  bottle was  fed with 250 ml of serum-free medium. 
About 50 ml of conditioned medium was harvested daily, with 50 ml 
of fresh medium  added,  for 3 weeks. A final  concentration of 10 mM 
benzamidine  and 0.15 mM phenylmethylsulfonyl fluoride was added 
into  the medium  collected. 
Isolation of Recombinant  Prothrombins-Briefly, 3.7 ml of 0.4 M 
sodium  citrate  and 0.1 ml of  1.0 M benzamidine were added to 100 ml 
of the cell-free medium containing  recombinant  prothrombin.  Pro- 
thrombin was precipitated  with  l/lOth volume of 1 M barium chloride, 
and  the precipit.ate  was  washed three  times  with 0.1 M barium chloride 
and 1 mM benzamidine. The precipitate was resuspended in 40% 
saturated ammonium sulfate and 0.2 M EDTA and subjected to 
centrifugation. The supernatant was then dialyzed against 20 mM 
Tris, 1 mM benzamidine, pH 7.4, overnight  and loaded onto a FPLC 
Mono Q ion-exchange  column  (HR 5/5, Pharmacia  LKB  Biotechnol- 
ogy, Inc.). The column was washed with 20 mM Tris,  pH 7.4, buffer, 
and  the  protein was eluted with a linear gradient from 0 to  0.7 M 
NaCl in the same buffer a t  1.5 ml/min. Protein absorbance was 
monitored a t  280 nm. The  identity of proteins  in  different  fractions 
was determined by sodium dodecyl-sulfate-polyacrylamide gel elec- 
trophoresis (SDS-PAGE), using prestained SDS-PAGE standards 
(Bio-Rad) and purified native prothrombin as the standard. The 
fractions  containing  pure  prothrombin were combined and  stored a t  
-70 'C for the following studies. 
y-Carboxyglutamic Acid Content of Recombinant Prothrombins - 
Prothrombin  fragment 1 was generated by cleavage of prothrombin 
with  thrombin coupled to  agarose beads. The resulting fragment 1 
and  prethrombin 1 were separated  on a FPLC  Mono Q column with 
a linear  gradient of NaCl (0-0.7 M) in 20 mM Tris,  pH 7.4, buffer. 
Taking  native  prothrombin  fragment 1 as  the  standard,  the relative 
y-carboxyglutamic acid (Gla)  content of fragment 1 of recombinant 
prothrombins was determined according to  the Gla-specific formal- 
dehyde-morpholine  Mannich base fragmentation  method  (Wright  et 
al., 1986). This  method  converts  the  10  Gla residues of prothrombin 
fragment 1 into  10  y-methyleneglutamyl residues and  can  quantita- 
tively  label the Gla  residues  when  [14-C]formaldehyde is used. Protein 
concentration of the modified fragment F1 was determined by ab- 
sorbance a t  280 nm  and 14C radioactivity of the modified fragment 
F1 was counted  on a LKB  1211  Rackbeta liquid scintillation  counter. 
Prothrombin Activation by Prothrombinase and Enzymatic Activity 
of the Activation Products-Mutant  recombinant  prothrombin, wild- 
type recombinant prothrombin, and native prothrombin (all at 1.2 
p M )  were activated  with 0.5 nM factor x,, 5 nM factor v,, 10 p M  PSI 
PC (25/75) SUV  and 5 mM CaC1' in 20 mM Tris, 150 mM NaCl, pH 
7.4, a t  22 "C.  At intervals of 0,5,  and 10 min,  aliquots were withdrawn 
and  subjected  to  SDS-PAGE (10% polyacrylamide) under  nonreduc- 
ing  and reducing (3% 2-mercaptoethanol)  conditions. Gels were 
stained  with Coomassie Blue R-250 (Sigma),  and  the  protein  bands 
were quantitated by densitometry (Molecular  Dynamics, Sunnyvale, 
CA) to  estimate  the  initial  rate of prothrombin  activation. 
Activation was also carried out at  37 "C and thereby taken to 
completion in 45 min. The product was thrombin in every case as 
shown by SDS-PAGE. An aliquot of each  incubation was taken  to 
measure  the  activity  toward  synthetic chromogenic substrate  52238 
and fibrinogen (Sigma). The measurements were performed simul- 
taneously  on a 96-well plate  with a Microplate  Reader (model 3550, 
Bio-Rad)  with  absorbance  read every 30 s a t  405 nm. For the  synthetic 
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FIG. 1. Schematic diagram of construction of the expression vector for recombinant prothrombins. 
The expression  vector  for the wild type (p437)  was  made  by subcloning  the EcoRI-Not1 fragment of p433 ( A )  into 
p272. The  mutant  prothrombin (Ser5*'+Ala) expression vector (p487) was made by subcloning the EcoRI-Not1 
fragment of p485 (B) into p272 (see  "Experimental Procedures" for details).  Resulting  vectors  are shown in C. 
chromogenic substrate assay, 5-pl  aliquots  (equal  to 0.45 pg of pro- 
thrombin), 60 p1 of 1 mM S2238, and 120 p1 of 20 mM Tris, 150 mM 
NaCI, pH 7.4 buffer were used. For  the fibrinogen clotting  assay, 2- 
p1 aliquots  (equivalent  to 0.18 pg of prothrombin), 140 p1 of 5  mg/ml 
fibrinogen, and 50 pl of 20 mM Tris, 150 mM NaC1, pH 7.4 buffer 
were  used, and  turbidity was recorded at the  same wavelength. 
Prothrombin Actiuation by Ecarin  and  Taipan Venom-Recombi- 
nant  prothrombins were also activated  with  ecarin  from E.  carinatus 
venom, which cleaves the Arg32'-Ile3'4 bond of bovine prothrombin 
(Rosing  and  Tans, 1988). Ecarin (12.5 Fg/ml final  concentration) was 
added  to a  final concentration of 90 pg/ml of native  or  recombinant 
prothrombin in 20 mM Tris, 150 mM NaC1, 6 mM CaC12, pH 7.4, 
buffer a t  37 "C  to  start  the  activation. At intervals of 0, 30, 90  min, 
20-pl aliquots were withdrawn and subjected to SDS-PAGE under 
both nonreducing and reducing conditions. Gels were stained with 
Coomassie  Blue  R-250. 
The DAPA fluorescence assay (Mann et al., 1981; Nesheim and 
Mann, 1983; Krishnaswamy  et al., 1986)  was also  applied to  compare 
the activation of mutant and native prothrombin by ecarin and 
Taipan venom. Taipan  snake venom  from 0. scutellatus is  known  to 
activate prothrombin to thrombin in the absence of factor V, a t  a 
rate that is enhanced 20-30 times by phospholipid vesicles (Owen 
and  Jackson,  1973). Using an  SLM 48000@ fluorometer  with  excita- 
tion wavelength a t  280 nm  and emission  wavelengths a t  515-550 nm 
with a 515-nm  cut-off  filter,  125 nM mutant or native  prothrombin, 
5 mM CaC12, and 500 nM DAPA in 20 mM Tris, 150 mM NaCl, pH 
7.4, buffer were incubated at 37 "C  for 3 min before  adding  100 pg/ 
ml ecarin or 10 pg/ml Taipan venom (final  concentrations) to  start 
the  reaction.  The  Taipan venom activation mixture also contained 
10 p~ PS/PC (25/75)  SUV. The fluorescence intensity of DAPA  was 
greatly enhanced when bound to the active site of newly formed 
meizothrombin or thrombin,  and  this allowing us  to record continu- 
ously the  time course of prothrombin  activation.  The fluorescence 
emission spectra of both  reaction  mixtures were also determined  from 
450 to  620 nm  (4-nm  bandpass)  with  an  excitation wavelength of  280 
nm  and a  450-nm  cut-off filter  in  the emission beam. 
DAPA Fluorescence Emission Intensity  Titration with Mutant or 
Native Thrombin--1.6 p~ mutant or native  prothrombin was incu- 
bated  with 50 pg/ml Taipan venom, 10 mM PS/PC (25/75)  SUV, and 
5 mM CaC12 in 20 mM Tris, 150 mM NaC1, pH 7.4, buffer at  22 "c 
judged by SDS-PAGE. 
overnight. Prothrombin was completely activated to thrombin as 
The activation  mixtures were then used to  titrate 150 nM DAPA 
in 20 mM Tris, 150 mM NaC1, pH 7.4, a t  22 "C by measuring DAPA 
fluorescence emission  intensity  using X,, = 280 nm  and X,, = 515- 
550 nm  with a 515 nm cut-off  filter. The  data were analyzed by the 
equation  (Nesheim et al., 1979; Hibbard  et al., 1982) 
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in which [PI,, and [I,],, are  the  nominal  concentrations of protein  and 
ligand, respectively; f and b are  the fraction of total ligand concentra- 
tion free and bound, respectively; n is  the  number of independent, 
noninteracting ligand-binding sites/protein molecule, and Kd is the 
dissociation constant. 
RESULTS 
FPLC and SDS-PAGE Behaviors of Native and Recombi- 
nant  Prothrombins -Recombinant  prothrombins isolated 
after barium precipitation  and ion-exchange FPLC were 
nearly homogeneous as judged  by SDS-PAGE (data not 
shown). Recombinant prothrombins migrated the same as 
native  prothrombin  on  SDS-PAGE  under  both  nonreducing 
and reducing conditions (Fig. 2). When  eluted  with a NaCl 
gradient from  a  Mono Q column, wild-type recombinant  pro- 
thrombin was eluted a t  21.14 min  and  mutant  recombinant 
prothrombin (Ser"'"+Ala) was eluted a t  21.01 min as com- 
pared  to 21.26 min  for  native bovine prothrombin.  After  the 
FPLC purification, the yields of wild-type and  mutant  pro- 
thrombin were 0.6-0.8 and 1.5-2.0 pg/ml of cell medium, 
respectively. 
Recombinant Prothrombins Possess Normal Gla Content- 
The relative y-carboxyglutamic acid (Gla) contents of the 
fragment 1 peptides isolated from recombinant and native 
prothrombins were determined by the Gla-specific [14C]form- 
aldehyde-morpholine  method  (Wright et al., 1986). This 
method specifically labels Gla residues with ['4C]formalde- 
hyde. The  results  are  presented  in  Table I, where  the specific 
"C radioactivity of each modified fragment 1 was  obtained 
using  the molecular  weight of 22,000 (Mann, 1976). Using  the 
ratio of the specific radioactivity of recombinant  prothrombin 
fragment 1 to  that of the  native molecule and a value of 10 
Gla residues/molecule (Nelsestuen et al., 1974) for native 
prothrombin  fragment 1, the  relative values of Gla  content of 
recombinant  prothrombin  fragment 1 were calculated (Jor- 
gensen et al., 1987). Mutant  recombinant  prothrombin  con- 
A 
B 
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FIG. 2. SDS-PAGE analysis of recombinant prothrombin 
activation by the full prothrombinase complex. Recombinant 
and  native  prothrombins (1.2 p ~ )  were activated  to  thrombin  with 
0.5 nM factor x,,, 5 nM factor v, 10 p M  Ps/Pc (25/75) suv, and 5 
mM CaC12 in 20 mM Tris, 150 mM NaC1, pH 7.4, a t  22 "c. At  intervals 
of 0, 5, and 10 min, aliquots were withdrawn  and  subjected  to  SDS- 
PAGE  under  nonreducing ( A )  and reducing (3% of 2-mercaptoetha- 
nol, R )  conditions. Lanes 1-3 are  native bovine prothrombin,  lanes 
4-6 are wild-type recombinant  prothrombin,  and lunes 7-9 are  mutant 
recombinant prothrombin (Ser"'"+Ala). The indicated bands in A 
are  a,  prothrombin; b, meizothrombin  des  fragment 1 or prethrombin 
1; c, thrombin;  and d, fragment 1. The  bands  in B are a, prothrombin; 
b, prethrombin 1; c, fragment 1.2 and/or thrombin B chain; d, 
lragment 1. 
TABLE I 
y-Carboxyglutamic  acid content of fragment I 
of recombinant Drothrombins 
Specific  y-Carboxyglutamic 
activity  acid conten  
dpmfpmol molfrnol 
Native  prothrombin F1 34.6 f 1.5 10.0" 
Mutant  prothrombin F1 34.3 f 1.6  9 9 f 0.5 
Wild-type  prothrombin F1 32.5 f 1.3 9.4 2 0.4 
" 10  Gla  residues/native  prothrombin  fragment 1 was taken  as  the 
standard  to  obtain  relative values  for the  recombinant molecules. 
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FIG. 3. Enzymatic activities of prothrombin activation 
products toward S2238 and fibrinogen. 1.2 PM native  or recom- 
binant prothrombins were activated with 0.5 nM factor X*, 5 nM 
factor v ,  10 p M  Ps/Pc (25/75) suv, and 5 mM CaCh in 20 mM 
Tris, 150 mM NaC1, pH 7.4, at 37 "C for 45 min. An aliquot of each 
incubation was taken  to  test  the  activity  toward  synthetic chromo- 
genic substrate S2238 ( A )  and fibrinogen ( B ) .  Data are shown in 
both figures  for native bovine prothrombin (circles),  wild-type recom- 
binant prothrombin (triangles), mutant recombinant prothrombin 
(squares),  and  the  control  incubation  without  prothrombin  (inverted 
triangles). 
tained 9.9 & 0.5 mol of Gla  residues/mol of fragment 1, and 
wild-type recombinant  prothrombin  contained 9.4 f 0.4 mol 
of Gla  residues/mol of fragment 1. 
Activation of Recombinant Prothrombins by Prothrombin- 
me-As shown  in Fig. 2, activation of wild-type recombinant 
prothrombin by the full prothrombinase complex was similar 
both in rate and extent of activation to the activation of 
native  prothrombin. By contrast,  the  activation of the  mutant 
prothrombin (Ser"8+Ala) was  much slower than  that of the 
native molecule under  the  same conditions. The  initial  rate 
of recombinant prothrombin activation relative to that of 
native  prothrombin,  as  quantitated  with  the  scanning densi- 
tometer, was 97% for wild-type prothrombin and 28% for 
mutant  prothrombin. 
Mutant  Thrombin Showed No  Activity Toward S2238 and 
Fibrinogen-Thrombin derived either from wild-type pro- 
thrombin  or  mutant  prothrombin by the  prothrombinase ac- 
tivation  was  tested  for  its  activities  toward  synthetic chro- 
mogenic substrate S2238 and fibrinogen and compared to 
native bovine thrombin (Fig. 3). As expected, wild-type 
thrombin  had  the  same  enzymatic  activities as native  throm- 
bin, while the  mutant  thrombin (SerS2'+Ala) displayed no 
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FIG. 4. SDS-PAGE analysis of recombinant prothrombin 
activation by ecarin. 12.5 pg/ml ecarin  (final  concentration) was 
added  to 90 p d m l  of native or recombinant  prothrombins  in 20 mM 
Tris, 150 mM NaCI, 6 mM CaC12, pH 7.4, buffer a t  37 "C to  start  the 
activation. At 0, 30, and 90 min, 20 pl of aliquot were withdrawn  and 
subjected to  SDS-PAGE  under  both  nonreducing ( A )  and reducing 
conditions ( 3 1  of 2-mercaptoethanol, B ) .  Lanes 1-3 are  native bovine 
prothrombin, lanes 4-6 are wild-type recombinant  prothrombin,  and 
lanes 7-9 are mutant recombinant prothrombin (Ser'"+Ala). The 
indicated  bands  in A are a, prothrombin; b, ecarin; c, meizothrombin 
des  fragment 1; and d, fragment 1. The  bands in B are a, prothrombin; 
h, ecarin; c, fragment 1.2-thrombin A chain; d, thrombin B chain; 
and e, fragment 1. 
activity  toward  these  substrates. 
The reaction mixtures of the recombinant prothrombins 
activated by Taipan  snake venom, in which thrombin  was  the 
activation  product as judged  by SDS-PAGE, were also  tested. 
The same results (data not shown) were obtained as were 
obtained  with  the  prothrombinase-derived  thrombin. 
SDS-PAGE Analysis of Recombinant Prothrombin Actiua- 
tion by Ecarin-When activated  with  ecarin, wild-type  recom- 
binant  prothrombin behaved the  same  as  native  prothrombin, 
as analyzed with  SDS-PAGE (Fig. 4) .  Activation of the wild- 
type  prothrombin was almost  completed a t  90 min,  and  most 
prothrombin was converted to meizothrombin  des  fragment 
1, which is the product of bovine meizothrombin autolysis 
(Rosing  and  Tans, 1988).  Activation of mutant  prothrombin 
was  also  completed by 90  min  as judged  by the reducing gel 
(Fig. 4B) ,  but the product was meizothrombin instead of 
meizothrombin des  fragment  1, showing mutant meizothrom- 
bin was not subject to  autolysis  as were the  native  and wild- 
type molecules. 
DAPA  Assay of Mutant  Prothrombin  Activation  by Ecarin 
or  Taipan Venom-When monitored  with  the DAPA  fluores- 
cence  assay, the emission intensity of the  mutant  prothrombin 
reaction  mixture  activated by ecarin (line 2, Fig. 5A)  reached 
a plateau  after 300 s. The  native  prothrombin  reaction mix- 
ture (line 1, Fig. 5A)  also  reached a maximum a t  about 300 s 
and subsequently declined. The  later  behavior  is  characteristic 
of formation of meizothrombin followed by its subsequent 
autolysis (Hibbard et al., 1982; Doyle and  Mann, 1990), as 
shown in the SDS-PAGE results in Fig. 4. Also consistent 
with Fig. 4, the  initially formed mutant  meizothrombin  was 
stable (line 2, Fig. 5A) .  
The  most  interesting  aspect of the  data  shown  in Fig. 5 is 
that  the fluorescence intensity of the  mutant  prothrombin 
activation  mixture was  only 33% of that of native molecule 
at the maximum when  activated by ecarin.  In  addition,  the 
fluorescence intensity  after  activation of mutant  prothrombin 
to thrombin  with  Taipan venom  was  only 40% of the fluores- 
I 
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FIG. 5. Mutant  recombinant  prothrombin  activation by 
ecarin or Taipan venom as continuously monitored with 
DAPA fluorescence emission intensity. The excitation wave- 
length was 280 nm  and emission  wavelengths were from 515 to 550 
nm with a 515-nm cut-off filter. Reaction  mixtures  containing 125 
nM native (line 1 )  or mutant  prothrombin (line 2) ,  500 nM DAPA, 
and 5 mM CaCI2 in 20 mM Tris, 150 mM NaC1, pH 7.4, a t  37 "c were 
initiated by the  addition of 120 pg/ml  ecarin ( A )  or 10 pg/ml Taipan 
venom ( B ) .  The  reaction  mixture ( B )  also contained 10 p M  PS/PC 
(25/75) SUV. 
cence intensity observed for  the  native  thrombin-DAPA com- 
plex. This could  be due  either  to reduced binding of DAPA or 
to a  reduced quantum yield of the  DAPA-mutant active site 
complex as  compared  to  the DAPA-native  active site complex. 
The DAPA fluorescence emission spectrum of the mutant 
prothrombin  reaction  mixture  activated by ecarin was similar 
(X,,, = 525 nm) to that of the native activation mixture, 
measured a t  about 300 s after  initiation of the  activation  (data 
not shown). The DAPA fluorescence emission spectrum of 
the  mutant  prothrombin  reaction  mixture  activated by Taipan 
snake venom  was also  similar (Xmax = 540 nm)  to  that of the 
native  activation  mixture  (data  not shown). 
Mutated Thrombin Active Site Showed a Weaker DAPA 
Binding Affinity-As titrated  with  the  same  amount f DAPA 
under  the  same  conditions,  the fluorescence intensity of the 
complex of DAPA and  mutant  thrombin was 74% of that of 
the complex of DAPA and  native  thrombin when both  titra- 
tions reached saturation  (data  not shown). Analysis of the 
titration  data  using  Equation 1 gave a stoichiometry n = 1.22 
mol of DAPA/mol of mutant  thrombin  and a dissociation 
constant Kd = 5.4 X M (Fig. 6B)  as contrasted to n = 
1.02 mol of DAPA/mol of native  thrombin  and K d  = 1.7 x 
lo-* M (Fig. 6A) .  By comparison, n = 1.20 & 0.14 mol of 
DAPA/mol of bovine thrombin  and K d  = (1.9 & 0.6) X 
M were reported by Hibbard et al. (1982). 
DISCUSSION 
The  catalytic  triad residues in  thrombin, as for other mem- 
bers of the serine protease family, are identified as His''Gfi, 
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FIG. 6. Analysis of DAPA titration  with  native  thrombin 
( A )  and mutant thrombin ( B ) .  1.6 ~ L M  native or mutant prothrom- 
bin was  incubated with 50  pg/ml Taipan venom, 10 mM PS/PC (25/ 
75) SUV, and 5 mM CaC12 in  20 mM Tris, 150 mM NaC1, pH 7.4, at 
22 "C overnight. The reaction mixtures were then used to titrate 150 
nM DAPA  in  20 mM Tris, 150 mM NaC1, pH 7.4, at 22 "C by measuring 
DAPA fluorescence emission intensity with X,, = 280 nm. Data were 
analyzed according to Equation 1 under "Experimental Procedures" 
(Nesheim et al., 1979;  Hibbard et al., 1982). 
and Ser'" (Mann et al., 1981). Because of the essential 
function of thrombin  in blood coagulation, no natural  pro- 
thrombin  mutated in any of these 3  catalytic residues is likely 
to be found. In the  current study, a mutant bovine prothrom- 
bin (Ser"""+Ala)  cDNA has been constructed, subcloned, and 
expressed in CHO. The expressed mutant recombinant pro- 
thrombin, as compared to native prothrombin, is fully y- 
carboxylated in CHO cells in the presence of vitamin  K at a 
yield of 1.5-2.0 pg/ml. The mutant prothrombin (Ser5"- 
Ala), with the same mobility as native prothrombin on an 
anion exchange FPLC column and on SDS-PAGE, can be 
activated to meizothrombin and  thrombin  as  are  native  and 
wild-type expressedprothrombin. The  mutant meizothrombin 
obtained by ecarin activation is very stable and does not 
undergo autolysis even in  the absence of thrombin active site 
inhibitors. Thus,  it provides a useful tool to examine the role 
of meizothrombin as  an  important  intermediate in prothrom- 
bin activation by the full prothrombinase. The availability of 
a  stable form of meizothrombin will  allow determination of 
the secondary or tertiary  structure of meizothrombin as well 
as of its interactions with other coagulation factors and with 
the phospholipid surface. The  mutant thrombin,  as expected, 
does not cleave fibrinogen and does not hydrolyze thrombin- 
specific chromogenic substrates. This inactive mutant  throm- 
bin is suitable for studying the binding interactions of throm- 
bin with its  substrate  and with inhibitors in the absence of 
catalysis. 
The successful expression of the  mutant prothrombin in 
vitro might also benefit crystallographic studies of prothrom- 
bin, thrombin, and even meizothrombin. So far, only the 
crystallographic structures of prothrombin fragment 1 and of 
thrombin inhibited with D-Phe-Pro-Arg chloromethylketone 
or hirudin have been reported (Tulinsky et al., 1988; Skrzyp- 
czak-Jankun et al., 1989; Bode et al., 1989; Rydel et al., 1990; 
Gliitter et al., 1990). 
DAPA, a specific inhibitor of the thrombin active site (& 
= 1.7 X lo-' M), does not bind to prothrombin or to prethrom- 
bin 1, in which both Arg274-Thr275 and Arg323-Ile324 remain 
intact, while it binds at a lower affinity ( K d  = 5.9 X M) 
to prethrombin 2, in which  Arg323-Ile324 is intact  and  the active 
site unexposed (Hibbard et al., 1982). Although the replace- 
ment of Ser5" by Ala in the mutant thrombin active site 
reduces its binding affinity to DAPA about 3-fold (& = 5.4 
X lo-" M), the affinity is still 10 times higher than  that of the 
DAPA-prethrombin 2 complex. In addition, the DAPA fluo- 
rescence emission spectrum of the  mutant thrombin has the 
same spectral features as that of native thrombin. These 
observations suggest that  the active site, after the Arg323-Ile324 
bond is cleaved, might be normally developed in the  mutant 
thrombin, despite any  disruption that might occur as  a result 
of the Ser5*$+Ala replacement. The weaker binding of the 
mutant  thrombin to DAPA reveals that Ser5" of the catalytic 
triad may be directly involved in DAPA binding, as recently 
shown for hirudin binding (Rydel et al., 1990). 
It is worthwhile to point  out that  the initial  rate of recom- 
binant  mutant  prothrombin activation by the full prothrom- 
binase is less than one-third the rate of native prothrombin 
activation, while the  rate of activation of recombinant wild- 
type prothrombin was the same as for native prothrombin. 
By comparison, the activation rates of recombinant mutant 
prothrombin by ecarin (at Arg?23-Ile324) and by Taipan  snake 
venom (at both Arg274-Thr275 and Arg?23-Ile324) were the same 
as for native prothrombin and for recombinant wild-type 
prothrombin. This suggests that  the mutation of Ser5" to Ala 
in the active site might alter  the environment or structure 
around Arg323-Ile324 in a way that could be sensed by the full 
prothrombinase, which activates  prothrombin through mei- 
zothrombin as  the intermediate (Rosing et al., 1986; Krish- 
naswamy et al., 1986). The prothrombin molecule has been 
shown to  interact functionally with each component of the 
prothrombinase, factor X,, factor V., Ca2+, and the phospho- 
lipid surface (Mann et al., 1988; Krishnaswamy 1990; Mann 
et al., 1990). The difference in the kinetics of activation 
between mutant recombinant prothrombin and the native 
molecule might be derived, then, from altered molecular in- 
teractions between mutant prothrombin and some compo- 
nents of the prothrombinase. Alternatively, meizothrombin 
may function as an important catalytic species within the 
prothrombinase complex. If so, meizothrombin would  be an 
ideal target for rational  antithrombotic drug design. Use of 
mutant  prothrombin  and  its activation products to investigate 
further  the details of these  interactions should lead to a  better 
understanding of the  structural basis of prothrombin activa- 
tion by prothrombinase. 
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